eligibility_summary
Inclusion: Adults 19–80 with CD20+ PCNSL, relapsed/refractory after ≤2 systemic and ≤1 RT, measurable enhancing brain lesion, ECOG ≤2, survival ≥3 mo, consent and lenalidomide PPP. Exclusion: Newly diagnosed, ocular-only or systemic disease, key lab/organ/cardiac issues, recent VTE/bleed/infection, HBV/HCV/HIV, dialysis, immunodeficiency/autoimmune/SCARs, other active cancers, dementia, no oral intake, hypersensitivity or prior lenalidomide/BTKi, pregnancy/inadequate contraception, poor adherence/substance abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm salvage trial in relapsed/refractory primary CNS lymphoma testing NB02 (poseltinib) + rituximab + lenalidomide (induction R2P, maintenance RP). Mechanisms and drug types: - Poseltinib (NB02): oral small-molecule, covalent BTK inhibitor, blocks B-cell receptor (BCR) signaling and downstream NF-kB/PI3K-AKT pathways, suppressing survival signaling in malignant B cells. - Rituximab: anti-CD20 chimeric monoclonal antibody, depletes CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. - Lenalidomide: oral IMiD, binds cereblon E3 ligase causing IKZF1/3 degradation, downregulates IRF4/MYC, enhances T- and NK-cell activity, and is anti-angiogenic. Targeted cells/pathways: CD20+ CNS lymphoma B cells, BCR/BTK/NF-kB signaling, cereblon-IKZF axis, immune effector (T/NK) pathways and complement.